FLECAINIDE ACETATE

Post-LOE

flecainide acetate

Humanwell Pharmaceutical

ANDAORALTABLET

Approved

Sep 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

FLECAINIDE ACETATE (flecainide acetate) by Humanwell Pharmaceutical is clinical pharmacology flecainide acetate has local anesthetic activity and belongs to the membrane stabilizing (class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the ic class of antiarrhythmics. Approved for — paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and 3 more indications. First approved in 2022.

Drug data last refreshed 23h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Flecainide acetate has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Electrophysiology In man, flecainide acetate produces a…

Worked on FLECAINIDE ACETATE at Humanwell Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

FLECAINIDE ACETATE

Mechanism of Action

Indications (6)